Literature DB >> 17927654

Headache associated with miller fisher syndrome.

Deborah I Friedman1, Eric Potts.   

Abstract

Miller Fisher syndrome, a variant of Guillain-Barre syndrome, is composed of the clinical triad of ophthalmoplegia, ataxia, and areflexia. A variety of other symptoms and signs have been reported in this syndrome, but headache is not a commonly reported symptom. We report a 35-year-old man with anti-GQ(1b) antibody-confirmed Miller Fisher syndrome presenting with severe and persistent headache, and we propose that the headache is caused by antibody-mediated effects on the trigeminovascular pain pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17927654     DOI: 10.1111/j.1526-4610.2007.00935.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  5 in total

Review 1.  Headache and Pain in Guillain-Barré Syndrome.

Authors:  Constantine Farmakidis; Seniha Inan; Mark Milstein; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2015-08

2.  A Case of Miller Fisher Syndrome, Thromboembolic Disease, and Angioedema: Association or Coincidence?

Authors:  Nooshin Salehi; Eric D Choi; Roger C Garrison
Journal:  Am J Case Rep       Date:  2017-01-16

3.  Miller Fisher Syndrome Mimicking Tolosa-Hunt Syndrome.

Authors:  Masahiro Oomura; Yuto Uchida; Keita Sakurai; Takanari Toyoda; Kenji Okita; Noriyuki Matsukawa
Journal:  Intern Med       Date:  2018-04-27       Impact factor: 1.271

4.  Case Report: Intracranial Hypertension Secondary to Guillain-Barre Syndrome.

Authors:  Christina Doxaki; Eleftheria Papadopoulou; Iliana Maniadaki; Nikolaos G Tsakalis; Konstantinos Palikaras; Pelagia Vorgia
Journal:  Front Pediatr       Date:  2021-01-20       Impact factor: 3.418

5.  Case Report: Guillain-Barré Syndrome Characterized by Severe Headache Associated With Metabotropic Glutamate Receptor 5 Antibody.

Authors:  Weiqian Yan; Cheng Zhao; Hainan Zhang; Zhiping Hu; Chunyu Wang
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.